Bolt Biotherapeutics Inc Revenue Growth Rates (BOLT), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Bolt Biotherapeutics Inc   (NASDAQ: BOLT)
 

BOLT's Revenue Growth by Quarter and Year

Bolt Biotherapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/BOLT/growth
https://api.csimarket.com/api/v1/companies/BOLT/fundamentals
https://api.csimarket.com/api/v1/companies/BOLT/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
BOLT Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 0.00
2nd Quarter June 0.01
1st Quarter March 0.03
FY 0.04

BOLTs Annual Revenue
Bolt Biotherapeutics Inc 's Revenue in the fiscal year 2025 $ 7.70 millions
Bolt Biotherapeutics Inc 's Revenue in the fiscal year 2024 $ 7.69 millions
Bolt Biotherapeutics Inc 's Revenue in the fiscal year 2023 $ 7.88 millions
Bolt Biotherapeutics Inc 's Revenue in the fiscal year 2022 $ 5.73 millions
Bolt Biotherapeutics Inc 's Revenue in the fiscal year 2021 $ 1.26 millions




BOLT Revenue third quarter 2026 Y/Y Growth Comment
Bolt Biotherapeutics Inc in the third quarter 2026 recorded of $ 0.00 millions.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 72 other companies have achieved higher Revenue growth. While Bolt Biotherapeutics Inc ' s Revenue meltdown of -100% ranks overall at the positon no. 1121 in the third quarter 2026.


BOLT Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June -99.44 %
1st Quarter March -97.54 %
FY   -

Financial Statements
Bolt Biotherapeutics Inc 's third quarter 2026 Revenue $ 0.00 millions BOLT's Income Statement
Bolt Biotherapeutics Inc 's third quarter 2025 Revenue $ 2.17 millions Quarterly BOLT's Income Statement


BOLT Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June -66.67 %
1st Quarter March -98.8 %
FY (Year on Year)   -


Back to BOLT Growth rate Comparisons >> Back to BOLT Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #73
Healthcare Sector #210
Overall #1121

Revenue Y/Y Growth Statistics
High Average Low
95.67 % 19.31 % -67.87 %
(Jun 30 2023)   (Mar 31 2025)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #73
Healthcare Sector #210
Overall #1121
Revenue Y/Y Growth Statistics
High Average Low
95.67 % 19.31 % -67.87 %
(Jun 30 2023)   (Mar 31 2025)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Bolt Biotherapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
1.0E+17 % 3.6206570688465E+15 % -100 %
 


BOLT's III. Quarter Q/Q Revenue Comment
Recent accomplishment of 0.00 millions by Bolt Biotherapeutics Inc come out even worse considering the 0.01 millions a quarter before.

Within Major Pharmaceutical Preparations industry 196 other companies have achieved higher Revenue quarter on quarter growth. While Bolt Biotherapeutics Inc 's Revenue growth quarter on quarter, overall rank is 3811.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #197
Healthcare Sector #555
Overall #3811
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #197
Healthcare Sector #555
Overall #3811
Revenue Q/Q Growth Statistics
High Average Low
1.0E+17 % 3.6206570688465E+15 % -100 %
 


BOLT's III. Quarter Q/Q Revenue Comment
Recent accomplishment of 0.00 millions by Bolt Biotherapeutics Inc come out even worse considering the 0.01 millions a quarter before.

Within Major Pharmaceutical Preparations industry 196 other companies have achieved higher Revenue quarter on quarter growth. While Bolt Biotherapeutics Inc 's Revenue growth quarter on quarter, overall rank is 3811.


Bolt Biotherapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 4.70
Y / Y Revenue Growth (TTM) 12.79 %
Year on Year Revenue Growth Overall Ranking # 3682
Seqeuential Revenue Change (TTM) -27.68 %
Seq. Revenue Growth (TTM) Overall Ranking # 1121


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Bolt Biotherapeutics Inc 's cumulative twelve months Revenue were $ 5 millions, company would post below average annual Revenue growth of -27.68% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Bolt Biotherapeutics Inc 's Revenue growth from the 0.01% growth in Mar 31 2026.

In the Healthcare sector 515 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2033 to 3682.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 73
Healthcare Sector # 516
Overall # 3682

Revenue TTM Y/Y Growth Statistics
High Average Low
95.67 %
 19.31 %
-67.87 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 73
Sector # 210
S&P 500 # 1121
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Bolt Biotherapeutics Inc 's cumulative twelve months Revenue were $ 5 millions, company would post below average annual Revenue growth of -67.87% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Bolt Biotherapeutics Inc 's Revenue growth from the 0.01% growth in Mar 31 2026.

In the Healthcare sector 515 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2033 to 3682.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 73
Healthcare Sector # 516
Overall # 3682

Revenue TTM Y/Y Growth Statistics
High Average Low
95.67 %
19.31 %
-67.87 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 73
Sector # 210
S&P 500 # 1121




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
BOLT's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue meltdown for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Viatris Inc -0.28%$ -0.277 millions
Zoetis Inc -0.38%$ -0.375 millions
Pfizer Inc-0.43%$ -0.426 millions
Standard Biotools Inc -0.51%$ -0.508 millions
Lucid Diagnostics Inc -0.66%$ -0.661 millions
Globus Medical Inc -0.69%$ -0.693 millions
Conmed Corporation-0.70%$ -0.701 millions
Surgery Partners Inc -0.75%$ -0.755 millions
Myriad Genetics Inc -1.03%$ -1.025 millions
Lensar Inc -1.29%$ -1.292 millions
Fortrea Holdings Inc -1.40%$ -1.397 millions
Immunocore Holdings Plc-1.42%$ -1.419 millions
Pacira Biosciences inc -1.59%$ -1.595 millions
Organon and Co -1.75%$ -1.748 millions
Teva Pharmaceutical Industries Limited-1.90%$ -1.897 millions
Skinhealth Systems Inc -2.07%$ -2.071 millions
Charles River Laboratories International inc -2.20%$ -2.201 millions
Inogen Inc -2.40%$ -2.399 millions
Novavax inc -3.05%$ -3.048 millions
Seer Inc -3.14%$ -3.139 millions
Teladoc Health Inc -3.41%$ -3.406 millions
Scientific Industries Inc -3.50%$ -3.504 millions
Cg Oncology Inc -3.72%$ -3.721 millions
Treace Medical Concepts Inc -3.91%$ -3.905 millions
Sarepta Therapeutics Inc -4.51%$ -4.509 millions
Pacific Health Care Organization Inc-4.69%$ -4.689 millions
Tela Bio Inc -5.06%$ -5.058 millions
Perrigo Company Plc-5.22%$ -5.225 millions
Heron Therapeutics Inc -5.49%$ -5.493 millions
Milestone Scientific Inc -5.95%$ -5.948 millions


About Bolt Biotherapeutics Inc Revenue Growth Rates (BOLT), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.